CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc., announced on September 25, 2025, a national agreement with UnitedHealthcare Insurance Company. Effective September 15, 2025, this agreement covers over 51 million people throughout the United States.
The agreement provides coverage for the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT). This LDT supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.
The CNSide® CSF Assay Platform has demonstrated superior clinical utility over standard of care, with 92% sensitivity and 95% specificity in over 11,000 tests performed since 2020. This national coverage is a critical step for the commercial success and broad adoption of CNSide.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.